NCT05532722View on ClinicalTrials.gov

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
T-cell Large Granular Lymphocytic Leukemia
Interventions
DRUG

ABC008

Given subcutaneous injection

Trial Locations (8)

10029

Icahn School of Medicine at Mount Sinai, New York

44195

Cleveland Clinic Foundation, Cleveland

77030

The University of Texas M.D. Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

90033

University of Southern California, Los Angeles

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Abcuro, Inc.

INDUSTRY